Stefan Oschmann, Merck KGaA CEO (Sipa USA via AP Images)

Mer­ck KGaA ear­marks $855M for De­bio­phar­m's pro­grammed cell death pro­mot­ing drug in glob­al li­cens­ing deal

Mer­ck KGaA, pri­mar­i­ly known for its CD­MO work, is play­ing with gi­ants in on­col­o­gy and look­ing at nov­el mech­a­nisms of ac­tion to com­pete. Now, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.